medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2016, Number 06

<< Back Next >>

Ginecol Obstet Mex 2016; 84 (06)

Postpartum choriocarcinoma stage IV. Case report

Ortiz-Sundheim Á, Verduzco-Rodríguez L

Language: Spanish
References: 20
Page: 383-389
PDF size: 373.53 Kb.


ABSTRACT

Background: In Mexico Trophoblastic disease occurs in 2.4 pregnancies for every 1000, mola invasive 1 each 40 molar pregnancies and choriocarcinoma in 1 of every 150,000 normal pregnancies. There have been reported few cases of postpartum choriocarcinoma stage IV, which is a very curable disease, the mean number of chemotherapy cycles is seven with successful results in 85%.
Case Report: Descriptive study of a case of postpartum Choriocarcinoma stage IV and its evolution with chemotherapy. Medical literature review used MeSH (Medical Subject Headings). Choriocarcinoma and Postpartum. Timely diagnosis as well as treatment based chemotherapy with adequate response and improvement of symptoms was done. The key point was to distinguish early signs and symptoms and use of early chemotherapy treatment.
Conclusions: The postpartum Choriocarcinoma is a rare entity, which tends to have a mortality rate between 10-15% independent of early diagnosis and treatment. The factors of pregnancy, with previous abortion, previous mola and hyperemesis with respiratory or neurological symptoms, as well as high quantification of beta subunit human chorionic gonadotropin (hCG) are very useful. The case presented here received early diagnosis, adequate treatment and follow-up.


REFERENCES

  1. Seckl MJ, Sebire NJ; Berkowitz RS. Gestational trophoblastic disease. Lancet 2010;376(9742):717-29.

  2. Sebire NJ, Foskett M, Paradinas FJ, Fisher RA, et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet 2002;359:165-166.

  3. Vaisbuch E, Ben-Arie A, Dgani R, Perlman S, et al. Twin pregnancy consisting of complete hydatiform mole and co-existent fetus: report of two cases and review literature. Gynecol Oncol 2005;98; 9-23.

  4. Rodabaugh KJ, Bernstein MR, Goldstein DP, Bercowitz RS. Natural history of postterm choriocarcinoma. J Reproduction Med 1998;43(1):75-80

  5. Dobson LS, Gillespie AM, Coleman RE, Hancock BW. The presentation and management of postpartum choriocarcinoma. Br J Cancer 1999;79(9-10):1531-3.

  6. Chapman-Davis E, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR. Gynecol Oncol 2012;125(3):572-5.

  7. Muller CY, Cole LA. The quagmire of hCG and hCG testing in gynecologic oncology. Gynecol Oncol 2009;112(3):663-72.

  8. AJCC Cancer staging manual. In: Edge SB, Byrd DR, Compton CC, et al. Gestational trophoblastic tumors. 7th ed. New York: Springer, 2010;439.

  9. FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009;105(1):3-4.

  10. El-Helw LM, Coleman RE, Everard JE, Tidy JE, et al. Impact of the Revised FIGO/Who system of the management of patients With gestational trophoblastic neoplasia. Gynecol Oncol 2009;113;306-311.

  11. Curry SL, Blessing JA, DiSaia PJ, Soper JT, Twiggs LB. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in “poor prognosis” metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Obstet Gynecol 1989;73(3 Pt 1):357-62.

  12. Lurain JR, Singh DK, Schink JC. Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7. J Reprod Med 2010;55(5- 6);199-207.

  13. Newlands ES, Holden L, Seckl MJ, McNeish, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med 2002; 47 (6); 465-71.

  14. Schmid P, Nagai Y, Agarwal R, Hancock B, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumors: a retrospective observational study. Lancet 2009;374(9683);48-55.

  15. Wright JD, Mutch DG. Treatment of high risk gestational trophoblastic tumors. Clin Obstet Ginecol 2003;46(3):593-606.

  16. Ma Y, Xiang Y, Wan XR, Chen Y, et al. The prognostic analysis of 123 postpartum choriocarcinoma cases. Int J Gynecol Cancer 2008;18(5):1097–1101.

  17. Palmer JE, Macdonald M, Wells M, Hancock BW, Tidy JA. Epithelioid trophoblastic tumor: a review of the literature. J Reprod Med 2008;53(7):465-75.

  18. Sita-Lumsden A, Short D, Lindsay I, Sebre NJ, et al. Treatment outcomes for 618 women with gestational trophoblastic tumors following a molar pregnancy at the Charing Cross Hospital. Br J Cancer 2012;107(11);1810-4.

  19. Matsui H, Iitsuka Y, Suzuka K, Yamazaka K, Mitsuhazhi A, Sekiya S. Salvage chemotherapy for high-risk gestational trophoblastic tumor. J Reprod Med 2004;49(6):438-42.

  20. Ngan HY, Kohorn EI, Cole LA, Kurman RJ, et al. Trophoblastic disease. Int J Gynaecol Obstet 2012;119(Suppl 2):S130-6.




2020     |     www.medigraphic.com